Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 5;9(2):20552173231165196. doi: 10.1177/20552173231165196

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2023

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 1. — Spike antibody levels (U/mL) in HC, fingolimod and ocrelizumab groups after 2nd and 3rd dose of vaccine shown on the y-axis. Patients are stratified by groups on the X axis. HC-2 vax (n = 29) indicates the HC group after 2 doses of vaccine; HC-3 vax (n = 7) indicates the HC group after 3 doses of vaccine. Fin-2 vax (n = 7) indicates the fingolimod group after 2 doses of vaccine; Fin-3 vax (n = 21) indicates the fingolimod group after 3 doses of vaccine; Ocr-2 vax (n = 33) indicates the ocrelizumab group after 2 doses of vaccine; Ocr-3 vax (n = 22) indicates the ocrelizumab group after 3 doses of vaccine. Statistical significance between groups is shown with **** symbolizing p < 0.0001.